Document:

Exhibit 4.8

 

Description of the Registrant’s Securities Registered Pursuant
to Section 12 of the Securities Exchange Act of 1934

 

As of December 31, 2021, Augmedix, Inc. (the
“Company,” “we,” or “our”) had one class of securities registered under Section 12 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”): our common stock.

 

The following description
summarizes the most important terms of our capital stock and certain provisions of our restated certificate of incorporation and restated
bylaws. Because it is only a summary, it does not contain all of the information that may be important to you. For a complete description,
you should refer to our restated certificate of incorporation and restated bylaws, which are incorporated by reference as an exhibit
to the Annual Report on Form 10-K of which this Exhibit 4.8 is a part, and to the provisions of applicable Delaware law.

 

Authorized Capital Stock

 

Our authorized capital stock consists of 500,000,000
shares of common stock, $0.0001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.0001 par value per share.

 

Common Stock

 

Dividend Rights 

 

Subject to preferences that may apply to any
shares of preferred stock outstanding at the time, the holders of our common stock are entitled to receive dividends out of funds legally
available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that
our board of directors may determine.

 

Voting Rights 

 

Holders of our common stock are entitled to one
vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election
of directors in our restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will
be able to elect all of our directors. Our restated certificate of incorporation established a classified board of directors, divided
into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders,
with the other classes continuing for the remainder of their respective three-year terms.

 

No Preemptive or Similar Rights 

 

Our common stock is not entitled to preemptive
rights, and is not subject to conversion, redemption or sinking fund provisions.

 

Right to Receive Liquidation Distributions

 

Upon our liquidation, dissolution or winding-up,
the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock
and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities
and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.

 

Preferred Stock

 

Our board of directors is authorized, subject
to limitations prescribed by Delaware law, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from
time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares
of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by our stockholders.
Our board of directors is also able to increase or decrease the number of shares of any series of preferred stock, but not below the
number of shares of that series then outstanding and not above the number of shares of that series authorized, without any further vote
or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights
that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while
providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect
of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our common stock
and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred stock.

 

Stock Options

 

As of December 31, 2021, we had outstanding stock
options to purchase an aggregate of 6,212,803 shares of our common stock, with a weighted-average exercise price of $1.75 per share
under the 2020 Plan.

 

     

     

    

 

Stock Appreciation Rights

 

As of December 31, 2021, we had outstanding stock
appreciation rights to purchase an aggregate of 370,578 shares of our common stock, with a weighted-average exercise price of $2.25
per share under the 2020 Plan.

 

Warrants

 

As of December 31, 2021, we had outstanding warrants
to purchase an aggregate of 2,753,408 shares of our common stock, with a weighted-average exercise price of $2.93 per share.

 

Other Convertible Securities

 

As of the date hereof, other than the securities
described above, we do not have any outstanding convertible securities.

 

Anti-Takeover Provisions 

 

The provisions of the Delaware General Corporation
Law (the “DGCL”), our restated certificate of incorporation and our restated bylaws could have the effect of delaying, deferring
or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect
of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first
with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly
or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could
result in an improvement of their terms.

 

Section 203 of DGCL

 

We are subject to the provisions of Section
203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly held Delaware corporation from engaging
in a “business combination” with an “interested stockholder” for a three-year period following the time that
this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under
Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the
following conditions:

 

	 	●	before
    the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted
    in the stockholder becoming an interested stockholder;

 

	 	●	upon
    consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
    owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes
    of

 

	 	●	determining
    the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans in some instances,
    but not the outstanding voting stock owned by the interested stockholder; or
	 	 	 
	 	●	at
    or after the time the stockholder became interested, the business combination was approved by our board and authorized at an annual
    or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not
    owned by the interested stockholder.

 

Section 203 defines a business
combination to include:

 

	 	●	any
    merger or consolidation involving the corporation and the interested stockholder; 
	 	 	 
	 	●	any
    sale, transfer, lease, pledge, or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;
    
	 	 	 
	 	●	subject
    to exceptions, any transaction that results in the issuance of transfer by the corporation of any stock of the corporation to the
    interested stockholder; 
	 	 	 
	 	●	subject
    to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of
    any class or series of the corporation beneficially owned by the interested stockholder; and 
	 	 	 
	 	●	the
    receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
    by or through the corporation. 

 

In general, Section 203 defines an interested
stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity
or person affiliated with or controlling or controlled by the entity or person.

 

    2

     

    

 

Restated Certificate of Incorporation and Restated Bylaw Provisions

 

Our restated certificate of incorporation and our restated bylaws
include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our management team or changes
in our board of directors or our governance or policy, including the following:

 

	 	●	Board
    Vacancies. Our restated bylaws and certificate of incorporation authorize generally only our board of directors to fill vacant
    directorships resulting from any cause or created by the expansion of our board of directors. In addition, the number of directors
    constituting our board of directors may be set only by resolution adopted by a majority vote of our entire board of directors. These
    provisions prevent a stockholder from increasing the size of our board of directors and gaining control of our board of directors
    by filling the resulting vacancies with its own nominees.

 

	 	●	Classified
    Board. Our restated certificate of incorporation and restated bylaws provide that our board of directors is classified into three
    classes of directors. The existence of a classified board of directors could delay a successful tender offeror from obtaining majority
    control of our board of directors, and the prospect of that delay might deter a potential offeror. See the section titled “Management”
    for additional information.
	 	 	 
	 	●	Directors
    Removed Only for Cause. Our restated certificate of incorporation provides that stockholders may remove directors only for cause.
	 	 	 
	 	●	Supermajority
    Requirements for Amendments of Our Restated Certificate of Incorporation and Restated Bylaws. Our restated certificate of incorporation
    provides that the affirmative vote of holders of at least 66 2/3% of our outstanding common stock are required to amend certain provisions
    of our restated certificate of incorporation, including provisions relating to the classified board, the size of the board of directors,
    removal of directors, special meetings, actions by written consent, and designation of our preferred stock. The affirmative vote
    of holders of at least 66 2/3% of our outstanding common stock are required to amend or repeal our restated bylaws, although our
    restated bylaws may be amended by a simple majority vote of our board of directors.

 

	 	●	Stockholder
    Action; Special Meetings of Stockholders. Our restated certificate of incorporation provides that our stockholders may not take
    action by written consent but may only take action at annual or special meetings of our stockholders. As a result, holders of our
    capital stock would not be able to amend our restated bylaws or remove directors without holding a meeting of our stockholders called
    in accordance with our restated bylaws. Our restated certificate of incorporation and our restated bylaws provide that special meetings
    of our stockholders may be called only by a majority of our board of directors, the chairman of our board of directors, or our chief
    executive officer, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our
    stockholders to force consideration of a proposal or for stockholders to take any action, including the removal of directors.

 

	 	●	Advance
    Notice Requirements for Stockholder Proposals and Director Nominations.  Our restated bylaws provide advance notice
    procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election
    as directors at our annual meeting of stockholders. Our restated bylaws also specify certain requirements regarding the form and
    content of a stockholder’s notice. These provisions may preclude our stockholders from bringing matters before our annual meeting
    of stockholders or from making nominations for directors at our annual meeting of stockholders. We expect that these provisions might
    also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of
    directors or otherwise attempting to obtain control of our Company.
	 	 	 
	 	●	No
    Cumulative Voting.  The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election
    of directors unless a corporation’s certificate of incorporation provides otherwise. Our restated certificate of incorporation
    and restated bylaws do not provide for cumulative voting.

 

    3

     

    

 

	 	●	Issuance
    of Undesignated Preferred Stock. We anticipate that after the filing of our restated certificate
    of incorporation, our board will have the authority, without further action by the stockholders, to issue up to 10,000,000 shares
    of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of
    directors. The existence of authorized but unissued shares of preferred stock enables our board of directors to render more difficult
    or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest, or otherwise.
	 	 	 
	 	●	Choice
    of Forum.    Our restated certificate of incorporation provides that, to the fullest extent permitted
    by law, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought
    on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL,
    our restated certificate of incorporation or our restated bylaws; or any action asserting a claim against us that is governed by
    the internal affairs doctrine. Our restated bylaws provide that the federal district courts of the United States of America will,
    to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under
    the Securities Act, which we refer to as a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision
    by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can
    be no assurance that federal courts or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal
    Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our
    stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought
    in state court. While neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any
    duty or liability created by the Exchange Act, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all
    claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Accordingly,
    actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder
    also must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the federal securities
    laws and the regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring or holding any interest in
    any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum
    Provision. These provisions may limit a stockholder’s ability to bring a claim in a judicial forum of their choosing for disputes
    with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers, and
    other employees.

 

Transfer Agent and Registrar 

 

The transfer agent and registrar for our common stock is VStock Transfer,
LLC. The transfer agent’s address is 18 Lafayette Place, Woodmere, NY 11598, and its telephone number is (212) 828-8436.

 

Exchange Listing 

 

Our common stock is listed on Nasdaq Stock Market LLC under the symbol
“AUGX.”

 

 

4Exhibit 10.1

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

This Executive Employment
Agreement (the “Agreement”), dated as of March 24, 2022, made between Enzo Biochem, Inc., a New York corporation, with
its principal office at 527 Madison Avenue, New York, New York 10022, (the “Company”) and David Bench (the “Executive”)
(collectively, the “Parties”).

 

Whereas,
Executive is currently a full-time employee of the Company; and

 

Whereas,
the Company desires for Executive to continue to provide services to the Company, and wishes to provide Executive with certain compensation
and benefits in return for such employment services; and

 

Whereas,
Executive wishes to continue to be employed by the Company and to provide personal services to the Company in return for certain compensation
and benefits;

 

Now,
Therefore, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

 

1. Employment
by the Company.

 

1.1 Term.
The Executive’s employment pursuant to this Agreement shall commence as of the date this agreement is executed by both parties (“Effective
Date”) and shall continue until terminated in accordance as provided in Section 4 (the “Contract Term”).
Subject to the terms contained herein, Executive’s employment shall be “at-will” and may be terminated by either side,
with or without notice, and without further obligation thereof.

 

1.2 Position.
Executive shall continue to serve as the Company’s Chief Financial Officer and assume the additional positions of Senior Vice President,
Treasurer, and Corporate Secretary. During Executive’s employment with the Company, Executive will devote Executive’s best
efforts and substantially all of Executive’s business time and attention to the business of the Company, except for approved vacation
periods and reasonable periods of illness or other incapacities permitted by the Company’s general employment policies.

 

1.3 Duties
and Location. Executive shall report to the Chief Executive Officer or a designee thereof. Notwithstanding the foregoing, the Company
reserves the right to change Executive’s direct report and assign other or additional duties or modify duties from time to time.
Executive’s primary office location shall be the Company’s office located in Farmingdale, New York. The Company reserves the
right to reasonably require Executive to perform Executive’s duties at places other than Executive’s primary office location
from time to time, and to require business travel.

 

1.4 Policies
and Procedures. The employment relationship between the Parties shall be governed by the general employment policies and practices
of the Company. Executive shall at all times comply with all applicable laws, rules, and regulations, including those promulgated by regulatory
and self-regulatory authorities, securities exchanges, and domestic and foreign agencies and authorities, as well as the Employee Handbook,
the Compliance Manual and any other internal policies and procedures established by the Company and made available to employees generally.

 

    1

     

    

 

2. Compensation.

 

2.1 Salary.
For services to be rendered hereunder, Executive shall receive a base salary at the rate of $300,000 per year (the “Base
Salary”), subject to standard payroll deductions and withholdings and payable in accordance with the Company’s regular
payroll schedule. Executive’s base salary may be reviewed and changed by the Company on notice to the Executive.

 

2.2 Annual
Bonus. Executive will be eligible for an annual discretionary bonus (the “Annual Bonus”), which will be based on
a fiscal year basis, unless otherwise determined by the Company (the “Bonus Period”). Executive’s target for
each Annual Bonus shall be 50% of Executive’s Base Salary (“Target”); provided, however, whether Executive receives
an Annual Bonus for any Bonus Period, and the amount of any such Annual Bonus, whether at, above, or below Target will be determined by
the Board or the compensation committee thereof in its sole discretion. The Annual Bonus, if payable, will be paid when bonuses are paid
to similarly situated executives, which shall be prior to seventy-five days following the conclusion of the Bonus Period. For the avoidance
of doubt, Executive will not be eligible for, and will not earn, any Annual Bonus if Executive’s employment terminates for any reason
before the Annual Bonus is to be paid, except Executive shall remain eligible for such Annual Bonus only if Executive’s employment
is terminated without Cause or if Executive resigns for Good Reason subsequent to the conclusion of the Bonus Period but prior to the
payment date of the Annual Bonus, as more specifically stated herein. Any Annual Bonus paid for any year shall not create any entitlement
to a bonus in a future year.

 

2.3 Sign-On
Bonus. On or about the first regular payroll run date following the Effective Date, Executive shall receive a sign-on bonus in the
amount of $55,000, less applicable deductions and withholdings (the “Sign-On Bonus”). Executive agree that in the event
of Executive’s termination for Cause or if Executive provides notice of Executive’s intent to terminate his employment without
Good Reason, in each case prior to the date that is three (3) months after the first date of the Contract Term, Executive shall be required
to immediately re-pay to the Company the gross amount of the Sign-On Bonus. This re-payment obligation shall not be deemed to be exclusive
of any other rights and remedies available to the Company.

 

2.4 Sign-On
Equity Grant. Subject to the approval of the Board and pursuant to the Company’s 2011 Amended and Restated Incentive Plan (the
“Plan”), Executive will be eligible to receive an option to purchase 87,500 shares (“Options”) of
the Company’s common stock at the fair market value as determined by the Board as of the date of grant (the “Option Grant”).
The Option Grant shall vest in equal one-third annual increments, with the first vesting on the first anniversary of the grant date provided
Executive remains employed in good standing on any such vesting date, and in all cases subject to the terms of the Plan and the Company’s
Option grant documents, the execution of which by Executive is required for any such grant.

 

2.5 Annual
Equity Grant. For each year of employment, subject to the approval of the Board and pursuant to the Plan, as hereinafter amended,
restated, or replaced, Executive shall be eligible for grants thereunder in an amount and pursuant to terms as determined by the Board
in its sole discretion. Each annual grant provided hereunder, if any, shall vest on terms as provided by the Company and shall be subject
to the terms of the Plan and the Company’s Option grant documents, the execution of which by Executive is required for any such
grant. Nothing herein requires the Board to make any grant under the Plan or otherwise.

 

    2

     

    

 

3. Transaction
Bonus. During the Contract Term, and provided Executive is still employed by the Company and has not given notice of his intent to
terminate his employment, upon consummation of a Change in Control (as defined herein), in addition to any other payments or benefits
applicable thereto under this Agreement, Executive shall be eligible to receive a Transaction Bonus equal to three quarters of one percent
(0.75%) of the “Transaction Value”, which means the total amount of Sale Proceeds paid in respect of the transaction that
resulted in the Change in Control. Said Transaction Bonus shall be paid 50% as soon as practicable following the closing date of the Change
in Control and 50% on the first anniversary thereof and shall be paid in the same form of consideration (e.g. cash, stock in the acquiring
company, promissory note or a combination thereof) as is the consideration received by the holders of the majority of the outstanding
voting securities of the Company who participate in the Transaction; provided, however, the Company reserves the right to pay the Transaction
Bonus in such other form as it determines in its sole discretion. For the sake of clarity, the computation of the Transaction Bonus and
whether Executive is eligible to receive same shall be determined in the Company’s sole discretion. Executive must be employed on
the payment date of either portion of the Transaction Bonus in order to be eligible for same provided, however, that such requirement
shall not apply in the event that, after a Change in Control but before payment of the remaining 50% of the Transaction Bonus is paid,
the Company terminates Executive’s employment without Cause or Executive terminates his employment for Good Reason, in either case
Executive shall receive the Transaction Bonus on the anniversary of the Change in Control as if Executive were still employed, subject
to the terms of Section 6. For the sake of clarity, “Sale Proceeds” shall mean the fair market value of the gross consideration
received by the Company or its stockholders in the Change in Control transaction, as determined by the Company in its sole discretion
immediately prior to the consummation of the Change in Control, taking into account such factors as the Committee deems appropriate, and
less, in all cases, (a) cash or cash equivalents held by the Company as of the date of the Change in Control, and (b) any expenses attributable
to the Change in Control.

 

“Change in Control” shall mean, in
respect of the Company any of (i) the beneficial ownership (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”)) of securities representing more than 50% of the combined voting power of Enzo is acquired by any “person”
as defined in sections 13(d) and 14(d) of the Exchange Act (other than the Company, any subsidiary of the Company, or any trustee or other
fiduciary holding securities under an employee benefit plan of the Company), (ii) the merger or consolidation of Enzo with or into another
corporation where the shareholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the
consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Exchange Act), directly or indirectly, shares
representing in the aggregate 50% or more of the combined voting power of the securities of the corporation issuing cash or securities
in the consolidation or merger (or of its ultimate parent corporation, if any) in substantially the same proportion as their ownership
of the Company immediately prior to such merger or consolidation, or (iii) the sale or other disposition of all or substantially all of
Enzo’s assets to an entity, other than a sale or disposition by the Company of all or substantially all of Enzo’s assets to
an entity, at least 50% of the combined voting power of the voting securities of which are owned directly or indirectly by shareholders
of the Company, immediately prior to the sale or disposition, in substantially the same proportion as their ownership of the Company.

 

4. Company
Benefits. Executive shall be eligible to participate in all employee benefit programs for which Executive is eligible under the terms
and conditions of the benefit plans that may be in effect from time to time and provided by the Company to its senior-level employees
including medical and dental insurance, life and disability insurance, and participation in the Company’s 401(k) retirement plan.
During the Contract Term, Executive shall further receive paid vacation and a car allowance as determined by the Company in its sole discretion.
The Company reserves the right to cancel or change the benefit plans or programs it offers to the Executive at any time; provided, however,
that any such change shall be across the board changes similarly affecting the eligibility requirements of all senior-level employees
of the Company.

 

    3

     

    

 

5. Termination
of Employment; Severance.

 

5.1 Employment.
During the Contract Term, either Executive or the Company may terminate Executive’s employment relationship at any time, provided,
however, that if Executive resigns during the Contract Term, Executive shall provide no less than ninety (90) days’ advance written
notice of any such termination (the “Notice Period”). During the Notice Period, Executive shall remain an employee
of the Company, and shall continue to receive Base Salary, but no other compensation. The Company may elect to have Executive not report
to work for all or any portion of such Notice Period. The Company shall have the right, at its sole discretion, to accelerate Executive’s
termination date to any date subsequent to receiving written notice from Executive, and thus conclude the Notice Period.

 

5.2 Termination
Without Cause or Good Reason.

 

a. The
Company may terminate Executive’s employment with the Company at any time with or without Cause (as defined below) during the Contract
Term.

 

b. If
Executive’s employment is terminated by the Company without Cause, or if Executive terminates his employment with Good Reason, the
Company shall pay Executive, as severance, (x) the equivalent of twelve (12) months of Executive’s Base Salary and (y) if the termination
date occurs subsequent to the conclusion of the fiscal year but prior to the payment of the Annual Bonus to which the fiscal year relates,
such Annual Bonus, if any, as computed in accordance with Section 2.2 above, subject to standard payroll deductions and withholdings (the
“Severance”). The Severance will be paid as a continuation on the Company’s regular payroll, beginning no later
than the first regularly-scheduled payroll date following the sixtieth (60th) day after Executive’s Separation from Service (as
defined below), provided the Separation Agreement (as discussed in Paragraph 5) has become effective and further provided that the Bonus
component under (y), if any, shall be paid in a lump sum on the sixtieth day after Executive’s Separation from Service..

 

c. 
Any stock options held by Executive as of the Effective Date of the Agreement or hereinafter granted shall provide for full vesting provided
Executive’s employment is terminated without Cause or if Executive terminates his employment with Good Reason or in a Change in
Control, subject to any other terms as provided in the Company’s incentive compensation program. Furthermore, all restricted stock
units shall become unrestricted immediately upon termination without Cause or Change in Control.

 

d. For
purposes of this Agreement, “Cause” for termination will mean: (a) commission of any (i) felony or (ii) crime involving
fraud, dishonesty or moral turpitude (whether or not a felony); (b) any action by Executive involving fraud, breach of the duty of loyalty,
malfeasance, willful misconduct, or negligence, (c) the failure or refusal by Executive to perform any material duties hereunder or to
follow any lawful and reasonable direction of the Company; (d) intentional damage to any property of the Company; (e) chronic neglect
or absenteeism in the performance of Executive’s duties; (f) willful misconduct, gross negligence, or other material violation of
Company policy or code of conduct that causes an adverse effect upon the Company; (g) breach of any written agreement with the Company
(including this Employment Agreement); or (h) any action that in the reasonable belief of the Board shall or potentially shall subject
the Company to material adverse publicity or effects. Prior to any termination for Cause under section (c), (e), (f), (g), or (h), the
Board shall provide Executive by written notice with ten (10) calendar days to cure same, provided any such actions underlying Cause are
determined by the Board to be curable. Any determination of Cause hereunder shall be made by the Board in its good faith discretion, which
shall only be made by the Board and, to the extent deemed practicable by the Board, after providing the Executive an opportunity to respond
to any determination or allegation of Cause.

 

    4

     

    

 

e. For
purposes of this Agreement, “Good Reason” for termination will mean: (i) material diminution of the Executive’s title
or duties below that of the level of aChief Financial Officer ; (ii) a material reduction in Executive’s Base Salary, other than
as required by exigent business circumstances; (iii) the Company requiring Executive to work on a full-time basis outside of the state
of New York; or (iv) a material and uncured breach by the Company of any provision of this Agreement. provided, that Executive shall give
written notice to the Company within thirty (30) days following the occasion of any allegation of Good Reason, and the Company shall have
thirty (30) days to cure same. In the event such occurrence is not cured, then Executive may terminate Executive’s employment for
Good Reason hereunder within ninety (90) days from the end of the cure period. The Executive’s continued employment prior to the
conclusion of the ninety (90) day period stated in the preceding sentence shall not constitute consent to, or waiver of rights with respect
to, any act or failure to act by the Company constituting “Good Reason” hereunder, if not cured in the preceding thirty day
period.

 

5.3 Termination
for Any Other Reason.

 

a. Upon
a termination for any reason other than without Cause or with Good Reason then upon Executive’s termination date all payments of
compensation by the Company to Executive hereunder will terminate immediately (except as to amounts already earned), and Executive will
not be entitled to any Severance.

 

b. In
the event of termination for any reason. Executive shall resign from all positions and terminate any relationships as an employee, advisor,
officer or director with the Company and any of its affiliates, each effective on the date of termination.

 

6. Conditions
to Receipt of Severance Benefits. In order to receive any Severance Benefits, the termination of Executive’s employment must
constitute a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative
definition thereunder, a “Separation from Service”), and Executive must be in compliance with the terms of this Agreement.
Further, the receipt of the Severance Benefits will be conditioned on Executive signing, not revoking, and complying with a separation
agreement and release of claims in a form reasonably satisfactory to the Company (the “Separation Agreement”). No Severance
Benefits will be paid or provided until the Separation Agreement becomes effective.

 

7. Section
409A. It is intended that all of the Severance and other payments payable under this Agreement satisfy, to the greatest extent possible,
the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9),
and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt,
this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For purposes of Code Section
409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive’s right to receive
any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to
receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate
and distinct payment.

 

    5

     

    

 

8. Restrictive
Covenants

 

8.1 Definitions.
The following capitalized terms used in this Agreement shall have the meanings assigned to them below, which definitions shall apply to
both the singular and the plural forms of such terms:

 

i “Confidential
Information” “Confidential Information” shall be given its broadest possible interpretation and shall mean
any and all information of the Company, its affiliates, subsidiaries, and parents (each, a “Company Entity”, and collectively,
“Company Entities”), including without limitation: (i) financial and business information relating to any Company Entity,
such as information with respect to costs, fees, profits, revenues, markets, mailing/client lists, strategies and plans for future business,
new business, product or other development, potential acquisitions or divestitures and new marketing ideas; (ii) product and technical
information relating to any Company Entity, such as software, software codes, computer models and research and development projects; (iii)
customer or investor information, such as the identity of any Company Entity’s clients or investors, the names of representatives
of Company Entity customer or investors responsible for entering into contracts with a Company Entity, the amounts paid by such investors
or customers to any Company Entity, specific customer or investor needs and requirements, specific customer or investor risk characteristics,
and specific customer or investor preferences; (iv) personnel information, such as the identity and number of any Company Entity’s
other employees and officers, their salaries, bonuses, benefits, skills, qualifications, and abilities; (v) any and all information in
whatever form relating to any customer or prospective customer of a Company Entity, including but not limited to its business, employees,
operations, systems, assets, liabilities, finances, products, and marketing, selling and operating practices; (vi) any information related
to any security system of any Company Entity or any of employees, (vii) any and all information pertaining to the business and or personal
affairs of the Company’s partners, members and employees, including but not limited to their personal lives, characteristics, opinions,
ideas, conduct, habits or background or their business or financial condition, affairs, dealings or operations or their personal database,
personal photographs or videotapes, purchases, travel itineraries, social interactions, tax information, emails, private conversations,
phone calls and correspondence; (viii) any information not included in (i) through (vii), above, which the Employee knows or should know
is subject to a restriction on disclosure or which the Employee knows or should know is considered by any Company Entity’s clients
or prospective clients to be confidential, sensitive, proprietary, or a trade secret or is not readily available to the public; or (ix)
intellectual property, including inventions and copyrightable works. Confidential Information is not generally known or available to the
general public, but has been developed, compiled, or acquired by the Company at its effort and expense. Confidential Information can be
in any form, including but not limited to verbal, written, or machine readable, including electronic files. By way of example but not
limitation of the foregoing, Confidential Information may be acquired by observing documents, things, people or events, by direct communication
with clients or others or by overhearing conversations in person or over the telephone or otherwise. “Confidential Information”
shall not include information that has become generally available to the public by the act of one who has the right to disclose such information
without violating any right or privilege of the Company.

 

    6

     

    

 

ii 
“Restricted Period” from the Start Date through the twelve-month anniversary of Executive’s Termination Date.

 

iii “Person”
means any individual or any corporation, partnership, joint venture, limited liability company, association or other entity or enterprise.

 

iv 
“Restricted Business” means any person, business, entity, organization or group within a larger firm that engages in,
or plans to engage in, (i) those parts of the business of the Company and any Company Entity with which you were involved during the employment
or about which you received Confidential Information, or (ii) any business activity which the Company or any Company Entity was actively
planning to engage in as of the Termination Date;

 

v “Restrictive
Covenants” means the covenants contained in this Section 7.

 

vi “Termination”
means the termination of Executive’s employment with the Company, for any reason, whether with or without Cause, upon the initiative
of either party.

 

vii “Termination
Date” means the date of Executive’s Termination.

 

viii “Work
Product” means all memoranda, summaries, written work product, business plans, formulas, recipes, inventions, innovations, improvements,
developments, methods, designs, analyses, drawings, reports and all similar or related information (whether patentable or not) that are
based upon Confidential Information and that are conceived, developed or made by Executive during his employment.

 

8.2 Restriction
on Disclosure and Use of Confidential Information. Executive agrees that Executive shall not, directly or indirectly, use any Confidential
Information on Executive’s own behalf or on behalf of any Person other than the Company, or reveal, divulge, or disclose any Confidential
Information to any Person not expressly authorized by the Company to receive such Confidential Information. This obligation shall remain
in effect for as long as the information or materials in question retain their status as Confidential Information. Executive further agrees
that he shall fully cooperate with the Company in maintaining the Confidential Information to the extent permitted by law. The parties
acknowledge and agree that this Agreement is not intended to, and does not, alter either the Company’s rights or Executive’s
obligations under any state or federal statutory or common law regarding trade secrets and unfair trade practices. Anything herein to
the contrary notwithstanding, Executive shall not be restricted from: (i) disclosing information that is required to be disclosed by law,
court order or other valid and appropriate legal process; provided, however, that in the event such disclosure is
required by law, Executive shall provide the Company with prompt notice of such requirement so that the Company may seek an appropriate
protective order prior to any such required disclosure by Executive; or (ii) reporting possible violations of federal, state, or local
law or regulation to any governmental agency or entity, or from making other disclosures that are protected under the whistleblower provisions
of federal, state, or local law or regulation, and Executive shall not need the prior authorization of the Company to make any such reports
or disclosures and shall not be required to notify the Company that Executive has made such reports or disclosures. Notwithstanding anything
in the foregoing to the contrary, in accordance with the Defend Trade Secrets Act of 2016, Executive will not be criminally or civilly
liable for disclosing a trade secret if it was disclosed: (1) to any government official or attorney in confidence directly or indirectly
for the sole purpose of reporting or investigating a suspected violation of law; (2) in a complaint or other document filed in a lawsuit
or other proceeding if filed under seal; or (3) to an attorney or used in a court proceeding in a retaliation lawsuit if any document
containing a trade secret is filed under seal and is not disclosed except pursuant to court order.

 

    7

     

    

 

8.3 Non-Competition
The Executive acknowledges and agrees that solely by reason of employment by the Company, the Executive has and will come into contact
with a significant number of the Company’s customers and prospective customers and have access to Confidential Information (as defined
herein) and trade secrets relating thereto, including those regarding the Company’s clients, prospective clients, proprietary business
models and strategies, and related information. Consequently, the Employee covenants and agrees that during the Restricted Period, Executive
shall not directly or indirectly, an individual proprietor, partner, stock-holder, officer, employee, director, joint venturer, investor,
lender, or in any other capacity whatsoever (other than as the holder of not more than three percent (3%) of the total outstanding stock
of a publicly held company), engage in the Restricted Business.

 

8.4 Non-Solicitation.
Executive agrees that, during the Restricted Period, he shall not, directly or indirectly, in his own capacity or through any other entity
or person: (i) solicit, persuade or induce any investor of the Company to terminate, reduce, disrupt or refrain from renewing or extending
its contractual or other relationship with the Company in regard to the purchase of products or services, procured, performed, manufactured,
marketed, or sold, by the Company; (ii) in any way interfere with the relationship between any such investor, client, supplier, licensee,
licensor, franchisee or business relation of the Company and/or any of its affiliates; (iii) induce or attempt to induce any employee
of the Company or any of its affiliates to leave the employ of the Company and/or any of its affiliates, or in any way interfere with
the relationship between the Company and/or any of its affiliates on the one hand and any employee thereof on the other hand; or (iv)
solicit to hire (other than through general advertisements for employment not directed at employees of the Company or any of its affiliates)
or hire any person who was an employee of any of the Company or any of its affiliates at any time during the one (1) year preceding such
solicitation.

 

8.5 Non-Disparagement.
Executive agrees that, at any time hereinafter, Executive will not do or say anything, including but not limited to communicating on the
internet (including but not limited to any posting or reference on any social networking site), or via e-mail, telephone, face-to-face
communication, or otherwise, that (i) criticizes or disparages the Company or its management, practices, policies, products or services;
(ii) disrupts or impairs the normal, ongoing business operations of Company, or any member of the Company Group; or (iii) harms the business
reputation of Company or the Company Group with its employees, customers, suppliers, contractors or the public. Executive will not discuss
any information (whether confidential or not) about the Company with any reporter, author, producer, or similar person or entity, or take
any other action seeking to publicize or disclose any such information in any way likely to result in such information being made available
to the general public in any form, including books, articles or writings of any kind, as well as film, videotape, audiotape or any other
medium or as commonly provided on a resume. Executive acknowledges and agree that these prohibitions extend to statements, written or
verbal, made to anyone and includes statements made via social media including on blogs or social networking sites, including but not
limited to Facebook, LinkedIn, or Twitter. Neither the Board nor the Company or any of its affiliates shall authorize any disparaging
comments about Executive. Notwithstanding the foregoing, nothing in this paragraph shall prevent either Executive, the Board or the Company
or any of its affiliates from making any truthful statement to the extent necessary with respect to any litigation, arbitration, or mediation
involving this Agreement, including, but not limited to, enforcement of this Agreement or as required by law or by any court, arbitrator,
mediator, or administrative or legislative body with actual or apparent jurisdiction to order such person to disclose or make accessible
such information.

 

    8

     

    

  

8.6 Return
of Materials. Executive agrees that Executive will not retain or destroy (except as set forth below), and will immediately return
to the Company on or, if specifically requested, prior to the Termination Date, or at any other time the Company requests such return,
any and all Company property, including Confidential Information and all other documents, materials, information, and property, including
but not limited to memoranda, letters, notes, plans, reports, analyses, recaps, jump drives, disks, tapes, journals, notebooks, and any
Company-provided computer, cell phone, Blackberry, beeper, keys, key fob, security card, phone card, credit cards, computer user name
and password, and/or voicemail code, all other files and documents relating to the Company and its business (regardless of form, but specifically
including all electronic files and data of the Company). Executive will not make, distribute, or retain copies of any such information
or property. Executive agrees that the ownership and right of control of all programs, databases, electronic files, reports, records and
supporting documents prepared by, for or on behalf of Executive in connection with the performance of Executive’s duties during
his employment are vested exclusively in the Company and remain the exclusive property of the Company.

 

8.7 Inventions.
Executive acknowledges and agrees that any and all Work Product, products, improvements, and inventions or creations conceived or made
by Executive during the period of Executive’s employment with the Company relating to the activities or business of the Company
or the Company Group are the sole and exclusive property of the Company or its nominee. Executive shall promptly disclose any Work Product
to the Company and perform all acts and things and sign whatever documents and agreements are necessary to confirm and vest the entire
right, title and interest in such Work Product in the Company, including copyright assignments, patent applications and other documents
and papers. Any assignment of Work Product includes all rights of attribution, paternity, integrity, modification, disclosure and withdrawal,
and any other rights throughout the world that may be known as or referred to as “moral rights,” “artist’s rights,”
“droit moral” or the like (collectively, “Moral Rights”). To the extent that Moral Rights cannot be assigned
under applicable law, Executive hereby waives and agrees not to enforce any and all Moral Rights, including, without limitation, any limitation
on subsequent modification, to the extent permitted under applicable law. Executive agrees to assist the Company, or its designee, at
its expense, in every proper way to secure the Company’s, or its designee’s, rights in the Company Inventions and any copyrights,
patents, trademarks, mask work rights, Moral Rights, or other intellectual property rights relating thereto in any and all countries,
including the disclosure to the Company or its designee of all pertinent information and data with respect thereto, the execution of all
applications, specifications, oaths, assignments, recordations, and all other instruments which the Company or its designee shall deem
necessary in order to apply for, obtain, maintain and transfer such rights, or if not transferable, waive and agree never to assert such
rights, and in order to assign and convey to the Company or its designee, and any successors, assigns and nominees the sole and exclusive
right, title and interest in and to such Company Inventions, and any copyrights, patents, mask work rights or other intellectual property
rights relating thereto. Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents
as Executive’s agent and attorney-in-fact, to act for and in Executive’s behalf and stead to execute and file any such instruments
and papers and to do all other lawfully permitted acts to further the application for, prosecution, issuance, maintenance or transfer
of patent, copyright, mask work and other registrations related to such Work Product. These obligations shall be binding upon Executive
and Executive’s heirs, assigns, executors, administrators, agents or other legal representatives. Executive may not use, disclose
to third parties or otherwise retain any such works or inventions, without the prior written permission of the Company.

 

    9

     

    

  

8.8 Cooperation
The Executive shall cooperate with the Company and its counsel in connection with any litigation or regulatory or self-regulatory inquiry,
investigation or proceeding relating to activities of Executive, or by activities of others of which the Executive may have knowledge,
and this obligation shall survive the termination of this Agreement. The Company shall reimburse the Executive for reasonable out-of-pocket
travel and other reasonable incidental expenses (other than legal expenses unless such legal expenses are requested by the Executive as
a result of divergent interests between Executive and the Company, and approved by the Board in writing) incurred as a result of the Executive’s
cooperation pursuant to the immediately preceding sentence.

 

8.9 Exceptions.
Nothing in this Agreement shall limit the rights of any government agency or any party’s right of access to, participation or cooperation
with any government agency. Notwithstanding anything to the foregoing, nothing herein, or in any other agreement or policy, shall limit
Executive’s right under applicable law to file a charge or complaint with the U.S. Equal Employment Opportunity Commission, the
National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission, or any other
federal, state or local governmental agency or commission (“Government Agencies”). Executive further understands that
this Agreement does not limit his ability to communicate with any Government Agencies or otherwise participate in any investigation or
proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company.
This Agreement does not limit Executive’s right to receive an award for information provided to any Government Agencies.

 

8.10 Enforcement
of Restrictive Covenants.

 

i Rights
and Remedies Upon Breach. The parties specifically acknowledge and agree that the remedy at law for any breach of the Restrictive
Covenants will be inadequate, and that in the event Executive breaches, or threatens to breach, any of the Restrictive Covenants, the
Company shall have the right and remedy, without the necessity of proving actual damage or posting any bond, to enjoin, preliminarily
and permanently, Executive from violating or threatening to violate the Restrictive Covenants and to have the Restrictive Covenants specifically
enforced by any court of competent jurisdiction, it being agreed that any breach or threatened breach of the Restrictive Covenants would
cause irreparable injury to the Company and that money damages would not provide an adequate remedy to the Company.

 

    10

     

    

 

ii Severability
and Modification of Covenants. Executive acknowledges and agrees that each of the Restrictive Covenants is reasonable and valid in
time and scope and in all other respects. The parties agree that it is their intention that the Restrictive Covenants be enforced in accordance
with their terms to the maximum extent permitted by law. Each of the Restrictive Covenants shall be considered and construed as a separate
and independent covenant. Should any part or provision of any of the Restrictive Covenants be held invalid, void, or unenforceable, such
invalidity, voidness, or unenforceability shall not render invalid, void, or unenforceable any other part or provision of this Agreement
or such Restrictive Covenant. If any of the provisions of the Restrictive Covenants should ever be held by a court of competent jurisdiction
to exceed the scope permitted by the applicable law, such provision or provisions shall be automatically modified to such lesser scope
as such court may deem just and proper for the reasonable protection of the Company’s legitimate business interests and may be enforced
by the Company to that extent in the manner described above and all other provisions of this Agreement shall be valid and enforceable.
The Restrictive Covenants shall survive the termination of the Contract Term and this Agreement.

 

9. Governing
Law; Dispute Resolution. The interpretation and application of this Employment shall be governed by the laws of the State of New York
without regard to principles of conflict of laws, other than laws which violate a fundamental public policy of the state of employ, in
which case such state’s laws shall govern with regard to such policies. Except for claims requesting injunctive relief, any dispute
or claim arising out of, in connection with, or relating to this Agreement (including without limitation its subject matter, interpretation,
or formation) or to Executive’s employment or relationship with the Company shall be resolved by binding arbitration to be held
in or around Farmingdale, New York, before three (3) arbitrators selected by the American Arbitration Association, conducted in accordance
with the then-prevailing Employment Arbitration Rules and Mediation Procedures of the American Arbitration Association. A copy of these
rules can be accessed through the American Arbitration Association’s website (www.adr.org). The arbitrators’ decision will
be final and binding in accordance with the Federal Arbitration Act and may be enforced in any court of competent jurisdiction. The arbitrators
will not have the right to modify or change any of the terms of this Employment Agreement. The arbitrators, and not any court, shall have
exclusive authority to resolve any dispute relating to the interpretation, applicability, enforceability or formation of this Employment
Agreement including any claim that all or any part of this Agreement is void or voidable. The parties agree that the arbitrators may provide
all appropriate remedies at law and equity and will have the power to summarily adjudicate claims and/or enter summary judgment in appropriate
cases. In any arbitration proceeding conducted pursuant to this paragraph, the parties shall have the right to discovery, to call witnesses,
and to cross-examine the other party’s witnesses.  The arbitrator shall render a final decision in writing, setting forth the
reasons for the arbitration award.  Both parties are bound by this agreement to arbitrate, but it does not include disputes, controversies
or differences which may not by law be arbitrated.  The parties agree that the arbitration proceedings described in this Section
are to be treated as confidential, and that the parties will act to protect the confidentiality of the documents, facts, and proceedings
related to the arbitration. THE PARTIES WAIVE THEIR RIGHT TO HAVE ANY SUCH DISPUTE, CLAIM OR CONTROVERSY DECIDED BY A JUDGE OR JURY IN
A COURT.  THE PARTIES ALSO AGREE THAT EACH MAY BRING CLAIMS AGAINST THE OTHER ONLY IN THEIR INDIVIDUAL CAPACITIES, AND NOT AS A PLAINTIFF
OR CLASS MEMBER IN ANY PURPORTED CLASS OR COLLECTIVE PROCEEDING.  THE PARTIES ALSO AGREE THAT EACH MAY NOT BRING CLAIMS AGAINST THE
OTHER IN ANY PURPORTED REPRESENTATIVE ACTION, EXCEPT TO THE EXTENT THIS STATEMENT IS UNENFORCEABLE UNDER THE LAW. All American Arbitration
Association filing fees, administrative costs, and arbitrator fees (as well as other related fees) shall be paid by the Company, with
the exception of fees that would be paid by the Executive should the dispute be settled in a Court of Law.

 

    11

     

    

 

10. General
Provisions.

 

10.1 Notices.
Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery, email, or the next day after
sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll.

 

10.2 Severability.
Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule
in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but
this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the
parties.

 

10.3 Waiver.
Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby be deemed to
have waived any preceding or succeeding breach of the same or any other provision of this Agreement.

 

10.4 Complete
Agreement. This Agreement constitutes the entire agreement between Executive and the Company with regard to this subject matter and
is the complete, final, and exclusive embodiment of the Parties’ agreement with regard to this subject matter, inclusive of any
earlier offer letter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those
expressly contained herein, and it supersedes any other such promises, warranties or representations. It is entered into without reliance
on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in a writing
signed by a duly authorized officer of the Company.

 

10.5 Counterparts.
This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all
of which taken together will constitute one and the same Agreement.

 

10.6 Headings.
The headings of the paragraphs hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect
the meaning thereof.

 

10.7 Successors
and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their
respective successors, assigns, heirs, executors and administrators. The Company may freely assign this Agreement, without Executive’s
prior written consent. Executive may not assign any of his duties hereunder and he may not assign any of his rights hereunder without
the written consent of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation,
assign or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform
this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken
place. As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business
and/or assets as aforesaid.

 

10.8 Background
Check and Ability to Work. This offer of employment is contingent upon verification of Executive’s identity and authorization
to legally work in the United States, a background and reference check, and all other Company practices and procedures as reasonably requested
by the Company.

 

10.9 Tax
Withholding . All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings of applicable
taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees
that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated
by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the
tax and economic consequences of all payments and awards made pursuant to the Agreement.

 

***

 

    12

     

    

 

You
acknowledge and agree that you have read and understand this Employment agreement and you voluntarily agree to the terms and conditions
contained herein.

 

We
look forward to you joining the Company. If you accept this offer of employment, please sign and return to me this Employment Agreement
attached by no later than March 27, 2022 or this offer shall expire.

 

In
Witness Whereof, the Parties have executed this Agreement on the day and year first written above.

 

	 	ENZO BIOCHEM INC.
	 	 
	 	By:	/s/ Hamid Erfanian     
	 	 
	 	Executive
	 	 
	 	/s/ David Bench

 

 

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]